JSPR

Jasper Therapeutics, Inc. (JSPR) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, primarily chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), using its lead candidate, briquilimab. The company has discontinued its asthma and stem cell transplant programs to focus resources on urticaria development.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Reduction in Net Loss: Net loss decreased by 94% to $1.2 million from $21.2 million in Q1 2025. This improvement was primarily driven by a $9.6 million gain from the change in fair value of warrant liabilities and a 50% reduction in operating expenses.
• Operating Expense Reduction: Total operating expenses fell to $11.0 million from $21.8 million. Research and Development (R&D) expenses dropped 64% to $5.8 million due to workforce reductions, the halting of the asthma study, and the discontinuation of SCID and MDS/AML programs.
• Cash Burn: Cash used in operating activities decreased to $14.5 million from $22.8 million, though the company still faces a significant cash outflow relative to its cash balance.
• Warrant Liability: The warrant liability decreased by $9.6 million due to a decline in the fair value of common stock warrants issued in September 2025.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the filing date. Current cash of $14.1 million is insufficient to fund operations without additional financing.
• Capital Needs: The company is actively seeking additional capital through equity or debt financings, collaborations, or a combination thereof. Failure to secure funding could force the company to delay, reduce, or eliminate R&D programs.
• Clinical Updates:
  • CSU (BEACON Study): Positive data reported with rapid onset of efficacy. An investigation into anomalous results in specific cohorts concluded the issue was related to patient selection criteria at certain sites, not the drug product.
  • CIndU (SPOTLIGHT Study): Positive preliminary data showing deep disease control.
  • Asthma (ETESIAN Study): Enrollment halted in July 2025; future development depends on capital availability and strategic partnerships.
• Legal Proceedings: The company is defending against a shareholder class action lawsuit alleging misstatements regarding clinical trials and two consolidated shareholder derivative complaints. No loss has been accrued as the outcome is uncertain.
• Restructuring: Cost reduction measures implemented in 2025 included workforce reductions and the cessation of vivarium operations, resulting in restructuring charges and asset impairments.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next financing round given the "substantial doubt" going concern disclosure and current cash balance of $14.1 million.
• Warrant Liability Volatility: Monitor the fair value of the $6.5 million warrant liability, as fluctuations significantly impact reported net income/loss without affecting cash flow.
• ATM Offering Capacity: Confirm the remaining capacity under the At-The-Market (ATM) offering ($93.5 million) and the impact of the public float limitation (one-third of public float rule) on fundraising ability.
• Legal Exposure: Track the status of the shareholder class action and derivative suits for potential settlement costs or reputational impact.
• Clinical Milestones: Review upcoming data readouts for the BEACON and SPOTLIGHT studies to assess the probability of advancing to Phase 2b/3 trials.